Carboplatin plus pemetrexed for platinum-pretreated, advanced non-small cell lung cancer: A retrospective study with pharmacogenetic evaluation

Cancer Chemotherapy and Pharmacology

Volumn 68, Issue 6, 2011, Pages 1405-1412

  Metro, Giulio ^a   Chiari, R ^a   Mare, M ^b   Giannarelli, D ^c   Tofanetti, F R ^a   Minotti, V ^a   Ferraldeschi, M ^a   Giuffrida, D ^b   Marcomigni, L ^a   Bennati, C ^a   Fischer, M J ^a   Meacci, M ^a   Bellavita, R ^a   Pistola, L ^a   Ludovini, V ^a   Crino L ^a  

^a Azienda Ospedaliera Santa Maria della Misericordia   (Italy)

^b Istituto Oncologico Del Mediterraneo   (Italy)

^c REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Carboplatin; Disease relapse; Non small cell lung cancer; Pemetrexed; Salvage chemotherapy; Single nucleotide polymorphisms

Indexed keywords

CARBOPLATIN; CISPLATIN; CYANOCOBALAMIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; ETOPOSIDE; FOLIC ACID; GEFITINIB; GEMCITABINE; PACLITAXEL; PEMETREXED;

ABNORMAL LABORATORY RESULT; ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER STAGING; CHEMORADIOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; DHFR GENE; DRUG DOSE SEQUENCE; DRUG ERUPTION; DRUG RESPONSE; DRUG SAFETY; DYSPEPSIA; ERCC1 GENE; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GARFT GENE; GENE; HOSPITALIZATION; HUMAN; HYPERCREATININEMIA; INCIDENCE; LEUKOPENIA; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PHARMACOGENETICS; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SALVAGE THERAPY; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT OUTCOME; TS GENE; XPD GENE; XRCC3 GENE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; DNA-BINDING PROTEINS; ENDONUCLEASES; FEMALE; GLUTAMATES; GUANINE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; RETROSPECTIVE STUDIES;

EID: 82455171877     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-011-1632-x     Document Type: Article

References (33)

1. J Ferlay DM Parkin E Steliarova-Foucher 2010 Estimates of cancer incidence and mortality in Europe in 2008 Eur J Cancer 46 765 781 20116997 10.1016/j.ejca.2009.12.014 1:STN:280:DC%2BC3c7js1CktA%3D%3D
2. A Jemal R Siegel J Xu E Ward 2010 Cancer statistics, 2010 CA Cancer J Clin 60 277 300 20610543 10.3322/caac.20073
3. S Ramalingam C Belani 2008 Systemic chemotherapy for advanced non-small cell lung cancer: recent advances and future directions Oncologist 13 Suppl 1 5 13 18263769 10.1634/theoncologist.13-S1-5 1:CAS:528:DC%2BD1cXivFGrt7o%3D
4. R Pirker JR Pereira A Szczesna J von Pawel M Krzakowski R Ramlau M Krzakowski R Ramlau I Vynnychenko K Park CT Yu V Ganul JK Roh E Bajetta K O'Byrne F de Marinis W Eberhardt T Goddemeier M Emig U Gatzemeier FLEX Study Team 2009 Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial Lancet 373 1525 1531 19410716 10.1016/S0140-6736(09)60569-9 1:CAS:528:DC%2BD1MXltlaqurs%3D
5. L Crinò E Dansin P Garrido F Griesinger J Laskin N Pavlakis D Stroiakovski N Thatcher CM Tsai YL Wu C Zhou 2010 Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study Lancet Oncol 11 733 740 20650686 10.1016/S1470-2045(10)70151-0
6. FV Fossella R DeVore RN Kerr J Crawford RR Natale F Dunphy L Kalman V Miller JS Lee M Moore D Gandara D Karp E Vokes M Kris Y Kim F Gamza L Hammershaimb 2000 Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group J Clin Oncol 18 2354 2362 10856094 1:CAS:528:DC%2BD3cXkvFWrsLg%3D (Pubitemid 30415821)
7. FA Shepherd J Dancey R Ramlau K Mattson R Gralla M O'Rourke N Levitan L Gressot M Vincent R Burkes S Coughlin Y Kim J Berille 2000 Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy J Clin Oncol 18 2095 2103 10811675 1:CAS:528:DC%2BD3cXktVyjsLc%3D (Pubitemid 30324363)
8. N Hanna FA Shepherd FV Fossella JR Pereira F De Marinis J von Pawel U Gatzemeier TC Tsao M Pless T Muller HL Lim C Desch K Szondy R Gervais R Shaharyar C Manegold S Paul P Paoletti L Einhorn PA Bunn Jr 2004 Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy J Clin Oncol 22 1589 1597 15117980 10.1200/JCO.2004.08.163 1:CAS:528:DC%2BD2cXpsVWmurk%3D (Pubitemid 41079796)
9. FA Shepherd J Rodrigues Pereira T Ciuleanu EH Tan V Hirsh S Thongprasert D Campos S Maoleekoonpiroj M Smylie R Martins M van Kooten M Dediu B Findlay D Tu D Johnston A Bezjak G Clark P Santabárbara L Seymour National Cancer Institute of Canada Clinical Trials Group 2005 Erlotinib in previously treated non-small-cell lung cancer N Engl J Med 353 123 132 16014882 10.1056/NEJMoa050753 1:CAS:528:DC%2BD2MXmtFaksbo%3D (Pubitemid 41058344)
10. LH de Lima Araújo CG Ferreira 2010 Platinum-based second-line treatment in non-small-cell lung cancer: an old new kid on the block? J Clin Oncol 28 24 25 10.1200/JCO.2009.25.1157
11. BA Teicher V Chen C Shih K Menon PA Forler VG Phares T Amsrud 2000 Treatment regimens including the multitargeted antifolate LY231514 in human tumor xenografts Clin Cancer Res 6 1016 1023 10741729 1:CAS:528: DC%2BD3cXisVaqu74%3D (Pubitemid 30159362)
12. GV Scagliotti C Kortsik GG Dark A Price C Manegold R Rosell M O'Brien PM Peterson D Castellano G Selvaggi S Novello J Blatter L Kayitalire L Crino L Paz-Ares 2005 Pemetrexed combined with oxaliplatin or carboplatin as first-line treatment in advanced non-small cell lung cancer: a multicenter, randomized, phase II trial Clin Cancer Res 11 690 696 15701857 10.1158/1078-0432.CCR-05-9009 1:CAS:528:DC%2BD2MXislWgtbk%3D (Pubitemid 40116896)
13. RG Zinner FV Fossella GW Gladish BS Glisson GR Blumenschein Jr VA Papadimitrakopoulou KM Pisters ES Kim YW Oh BO Peeples Z Ye RE Curiel CK Obasaju WK Hong RS Herbst 2005 Phase II study of pemetrexed in combination with carboplatin in the first-line treatment of advanced nonsmall cell lung cancer Cancer 104 2449 2456 16258975 10.1002/cncr.21480 1:CAS:528:DC%2BD2MXhtlWgt7bE (Pubitemid 41691567)
14. R de las Peñas M Sanchez-Ronco V Alberola M Taron C Camps R Garcia-Carbonero B Massuti C Queralt M Botia R Garcia-Gomez D Isla M Cobo M Santarpia F Cecere P Mendez JJ Sanchez R Rosell Spanish Lung Cancer Group 2006 Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine- treated non-small-cell lung cancer patients Ann Oncol 17 668 675 10.1093/annonc/mdj135
15. M Joerger A Omlin T Cerny M Früh 2010 The role of pemetrexed in advanced non small-cell lung cancer: special focus on pharmacology and mechanism of action Curr Drug Targets 11 37 47 19839929 10.2174/138945010790030974 1:CAS:528:DC%2BC3cXisVCisbk%3D
16. R Rami-Porta JJ Crowley P Goldstraw 2009 The revised TNM staging system for lung cancer Ann Thorac Cardiovasc Surg 15 4 9 19262443
17. P Therasse SG Arbuck EA Eisenhauer J Wanders RS Kaplan L Rubinstein J Verweij M Van Glabbeke AT van Oosterom MC Christian SG Gwyther 2000 New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 205 216 10655437 10.1093/jnci/92.3.205 1:STN:280:DC%2BD3c7it1Gitg%3D%3D
18. Common Terminology Criteria for Adverse Events v3.0 (CTCAE). Available at: ctep.cancer.gov/reporting/ctc.html [Last Accessed 1 January 2010]
19. C Ulrich J Bigler C Velicer E Greene F Farin J Potter 2000 Searching expressed sequence tag databases: discovery and confirmation of a common polymorphism in the thymidylate synthase gene Cancer Epidemiol Biomark Prev 9 1381 1385 1:CAS:528:DC%2BD3MXktFahsg%3D%3D (Pubitemid 32044809)
20. C Tibaldi E Giovannetti E Vasile V Mey AC Laan S Nannizzi R Di Marsico A Antonuzzo C Orlandini S Ricciardi M Del Tacca GJ Peters A Falcone R Danesi 2008 Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients Clin Cancer Res 14 1797 1803 18347182 10.1158/1078-0432.CCR-07-1364 1:CAS:528:DC%2BD1cXjtleju78%3D (Pubitemid 351469466)
21. EF Smit SA Burgers B Biesma HJ Smit P Eppinga AM Dingemans M Joerger JH Schellens A Vincent N van Zandwijk HJ Groen 2009 Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer J Clin Oncol 27 2038 2045 19307503 10.1200/JCO.2008.19.1650 1:CAS:528:DC%2BD1MXls1CgtLY%3D
22. Tiseo M, Boni L, Passalacqua R, Camerini A, Labianca R, Amadori D, Boni C, Giuffreda L, Di Costanzo F, Ardizzoni A (2010) Randomized phase II study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small cell lung cancer (GOIRC 02/2006): preliminary results. Ann Oncol 21(suppl 8): abs 414
23. HS Kim GW Lee JH Kim HY Kim JH Kwon HH Song HJ Kim JY Jung G Jang DR Choi SM Park TR Shin HS Lee DY Zang 2010 A phase II study of pemetrexed and carboplatin as a salvage therapy for platinum-pretreated patients with non-small cell lung cancer Lung Cancer 70 71 76 20096475 10.1016/j.lungcan.2009.12.015
24. M Di Maio N Lama A Morabito EF Smit V Georgoulias K Takeda E Quoix D Hatzidaki FM Wachters V Gebbia CM Tsai C Camps W Schuette P Chiodini MC Piccirillo F Perrone C Gallo C Gridelli 2010 Clinical assessment of patients with advanced non-small-cell lung cancer eligible for second-line chemotherapy: a prognostic score from individual data of nine randomised trials Eur J Cancer 46 735 743 20045311 10.1016/j.ejca.2009.12.013
25. T Nagano YH Kim K Goto K Kubota H Ohmatsu S Niho S Niho K Yoh Y Naito N Saijo Y Nishiwaki 2010 Re-challenge chemotherapy for relapsed non-small-cell lung cancer Lung Cancer 69 315 318 20071052 10.1016/j.lungcan.2009.11.016
26. JS Ryu YC Hong HS Han JE Lee S Kim YM Park YC Kim TS Hwang 2004 Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy Lung Cancer 44 311 316 15140544 10.1016/j.lungcan.2003.11.019 (Pubitemid 38609439)
27. D Isla C Sarries R Rosell G Alonso M Domine M Taron G Lopez-Vivanco C Camps M Botia L Nuñez M Sanchez-Ronco JJ Sanchez M Lopez-Brea I Barneto A Paredes B Medina A Artal P Lianes 2004 Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer Ann Oncol 15 1194 1203 15277258 10.1093/annonc/mdh319 1:STN:280: DC%2BD2cznt1Wmtw%3D%3D (Pubitemid 39199306)
28. W Zhou S Gurubhagavatula G Liu S Park DS Neuberg JC Wain TJ Lynch L Su DC Christiani 2004 Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy Clin Cancer Res 10 4939 4943 15297394 10.1158/1078-0432.CCR-04-0247 1:CAS:528:DC%2BD2cXmtlSitr4%3D (Pubitemid 39099767)
29. S Gurubhagavatula G Liu S Park W Zhou L Su JC Wain TJ Lynch DS Neuberg DC Christiani 2004 XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy J Clin Oncol 22 2594 2601 15173214 10.1200/JCO.2004.08.067 1:CAS:528: DC%2BD2cXpsVWksLo%3D (Pubitemid 41103746)
30. N Viñolas M Provencio N Reguart F Cardenal V Alberola JM Sánchez-Torres FJ Barón M Cobo I Maestu I Moreno C Mesía A Izquierdo E Felip M López-Brea A Márquez M Sánchez-Ronco M Tarón MC Santarpia R Rosell Spanish Lung Cancer Group 2011 Single nucleotide polymorphisms in MDR1 gen correlates with outcome in advanced non-small-cell lung cancer patients treated with cisplatin plus vinorelbine Lung Cancer 71 191 198 20627363 10.1016/j.lungcan.2010.05.005
31. B Blömeke WP Bennett CC Harris PG Shields 1997 Serum, plasma and paraffin-embedded tissues as sources of DNA for studying cancer susceptibility genes Carcinogenesis 18 1271 1275 9214613 10.1093/carcin/18.6.1271 (Pubitemid 28132521)
32. JM Rae KE Cordero JO Scheys ME Lippman DA Flockhart MD Johnson 2003 Genotyping for polymorphic drug metabolizing enzymes from paraffin-embedded and immunohistochemically stained tumor samples Pharmacogenetics 13 501 507 12893988 10.1097/00008571-200308000-00008 1:CAS:528:DC%2BD3sXlvV2jtL4%3D (Pubitemid 37034592)
33. S Marsh MA Mallon P Goodfellow HL McLeod 2005 Concordance of pharmacogenetic markers in germline and colorectal tumor DNA Pharmacogenomics 6 873 877 16296950 10.2217/14622416.6.8.873 1:CAS:528:DC%2BD28XitF2gtA%3D%3D (Pubitemid 41724361)